Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host…